What Is Retatrutide? The Triple-Agonist GLP-1 Explained

TL;DR

Retatrutide is an investigational peptide from Eli Lilly that activates three hormone receptors: GIP, GLP-1 and glucagon. It is often called a triple agonist or a next-generation GLP-1 medicine. It is not FDA-approved and is not available as a prescription treatment.

Trials have reported substantial average weight loss, but results describe selected participants under research supervision. They do not establish that an online product is safe, authentic or equivalent to the trial medicine. This PeptIQ.io guide explains the science and status without giving a treatment protocol. Talk to a licensed clinician about approved options for your own care.

What Retatrutide Is

Retatrutide, also called LY3437943, is one molecule designed to activate three receptors. An agonist activates a receptor; “triple” identifies its three targets. It does not mean three medicines mixed together, and the receptor count is not a score for how well a treatment will work for an individual.

Lilly describes retatrutide as an investigational once-weekly treatment. That describes its study design, not instructions for taking it. Its development program examines obesity and related conditions. The distinction between a molecule being studied and a medicine approved for patients matters throughout this guide. Lilly's retatrutide overview describes the research program.

“Peptide” describes the molecule's chemistry. It does not establish approval, manufacturing quality or suitability for you. A research name on a website cannot substitute for the clinical product, controlled trial setting or regulatory review.

How a Triple Agonist Differs From Semaglutide and Tirzepatide

The comparison begins with receptor targets:

• Semaglutide: activates GLP-1 receptors.
• Tirzepatide: activates GIP and GLP-1 receptors.
• Retatrutide: activates GIP, GLP-1 and glucagon receptors.

GLP-1 stands for glucagon-like peptide-1. Despite the similar names, GLP-1 and glucagon are different receptor targets. Adding glucagon activity is what distinguishes retatrutide from tirzepatide in this comparison. The diagram shows which receptors are targeted, without claiming equal activity at each receptor or predicting weight loss.

FDA describes tirzepatide's GIP and GLP-1 activity as helping reduce appetite and food intake. For more context, read what tirzepatide is and the three-drug mechanism comparison. The FDA Zepbound approval announcement also explains the dual-agonist mechanism.

A useful question is whether a treatment has evidence for the person's condition, with tolerable risks and an approved route to care. Counting receptors alone cannot answer that question. Nor does adding a receptor prove that all the benefits or warnings of another medicine transfer unchanged.

What the Trials Have Reported

Phase 2: the 2023 NEJM trial

The randomized, placebo-controlled phase 2 study enrolled 338 adults with obesity, or overweight plus a weight-related condition. At 48 weeks, the highest dose studied produced 24.2% mean weight reduction, compared with 2.1% with placebo. These were group averages, not a promised outcome. The primary endpoint was measured at 24 weeks; the 48-week result was a secondary endpoint. The study was funded by Lilly. Read the NEJM abstract on PubMed.

Phase 3: TRIUMPH results

In its December 2025 TRIUMPH-4 announcement, Lilly reported 28.7% average weight reduction at 68 weeks, versus 2.1% with placebo, for the highest dose studied under the efficacy analysis. The study involved adults with obesity or overweight and knee osteoarthritis, without diabetes.

That analysis estimates results with continued treatment and without prohibited weight-management treatments. The treatment-regimen analysis, which accounts for outcomes regardless of adherence, reported 23.7% versus 4.6%. Both belong to the same trial; the difference shows why the analysis method matters. Lilly's TRIUMPH-4 release.

Lilly's June 2026 TRIUMPH-1 presentation reported 28.3% average weight reduction at 80 weeks for the highest dose studied. It also presented a longer extension, but an extension population should not be treated as interchangeable with everyone originally enrolled. This guide uses the 80-week finding and leaves the extension headline out of its comparison. TRIUMPH-1 presentation.

How to read those numbers

These findings are encouraging research results. They are not a head-to-head ranking against semaglutide or tirzepatide. Trial populations, follow-up periods and statistical methods differ. A percentage without those details can make two studies look more comparable than they are.

Keep three questions next to any headline: Who was studied? Over what period? Under which analysis? Also distinguish a peer-reviewed paper from a company announcement or conference presentation. Here, the phase 2 citation is a published paper; the phase 3 figures are explicitly attributed to Lilly's materials. None supplies an individual treatment plan.

Side Effects Reported in Trials

Benefits need to be read alongside adverse events and treatment discontinuations:

• Gastrointestinal effects: the phase 2 paper described these as the most common adverse events, mostly mild to moderate. TRIUMPH-4 reported nausea, diarrhea, constipation and vomiting among common events.
• Heart rate: phase 2 reported increases that peaked at 24 weeks and then declined. That observation does not establish long-term cardiovascular safety.
• Dysesthesia: TRIUMPH-4 reported this altered-sensation adverse event in 20.9% of participants at the highest dose studied, versus 0.7% with placebo; events were generally mild. See the retatrutide side effects and dysesthesia guide.

Those findings come from the phase 2 abstract and TRIUMPH-4 release. In TRIUMPH-1, Lilly reported discontinuation because of adverse events in 4–11% across retatrutide groups, compared with 5% on placebo; GI events were the most common reason. TRIUMPH-1 safety presentation.

“Mild to moderate” describes a study classification, not permission to dismiss a symptom. Trial observations also cannot quantify the additional risks of an unverified online product. If you have used something sold as retatrutide, tell a licensed clinician what you used and what symptoms occurred.